Frailty and pre-frailty associated with long-term diminished physical performance and quality of life in breast cancer and hematopoietic cell transplant survivors (IMAGE)
Caption
Figure 1. Comparison of senescence with frailty in breast cancer and bone marrow transplant survivors. Whole blood from breast cancer (BC) survivors or hematologic malignancy patients treated with allogeneic hematopoietic cell transplantation (HCT) was used to CD3+ peripheral blood mononuclear cells (PBMCs) by magnetic bead purification. Total RNA was used to quantify expression of the cellular senescence marker p16INK4a by qPCR. Expression was normalized to 18S. Values represent the median with 95% confidence interval. Students unpaired two-tailed t test. ** p<0.01, ns (not significant).
Credit
2024 Jurdi et al.
Usage Restrictions
Original content
License
Original content